Latest news with #GMP-compliant
Business Upturn
15 hours ago
- Health
- Business Upturn
Super Feels Kava Kratom Shot Announces Official Website Update Featuring Natural Daily Supplement for Mood and Relaxation Support
FORT LAUDERDALE, June 07, 2025 (GLOBE NEWSWIRE) — Super Feels Kava Kratom Shot, a plant-based wellness solution developed by Super Speciosa, has updated its official website to share new information about its daily supplement formulated to support mood balance and natural relaxation in adults. Now available across the U.S., the convenient liquid shot is designed for individuals seeking a natural, on-the-go wellness solution rooted in traditional botanicals. According to the official product website ( Super Feels is intended to work in harmony with the body's systems to support a sense of calm and well-being through its unique combination of kratom leaf extract and noble kava root. The company positions the product as a ready-to-use formula that easily integrates into modern lifestyles without the need for pills or powders. 'We wanted to create something portable, natural, and approachable—something people can use to help manage life's daily stressors in a more mindful way,' said a spokesperson for Super Speciosa. 'This product reflects our commitment to clean formulation and botanical tradition.' The company states that Super Feels Kava Kratom Shot is manufactured in GMP-compliant facilities that prioritize rigorous quality control and ingredient sourcing. It is crafted to meet the needs of adults seeking a plant-based option to support relaxation and mental clarity without artificial additives. As noted on the product website, Super Feels includes a satisfaction guarantee for first-time buyers. Those interested in exploring the formulation's functional use cases or ordering directly can access detailed information, customer FAQs, and secure checkout at the official site. About Super Feels by Super Speciosa Super Feels is part of Super Speciosa, a Florida-based wellness brand dedicated to premium kratom and herbal-based solutions. With a focus on transparency and natural sourcing, the company creates functional plant-based products that support modern wellness goals. Product and Contact Information Brand: Super Feels by Super Speciosa Website: Email: [email protected] Phone: +1 (888) 958-5401 Mailing Address: 727 NE 3rd Ave, Suite 201, Fort Lauderdale, FL 33304, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
19 hours ago
- Health
- Yahoo
Super Feels Kava Kratom Shot Announces Official Website Update Featuring Natural Daily Supplement for Mood and Relaxation Support
Plant-Based Kava and Kratom Shot Offers Natural Support for Mood, Relaxation, and Daily Wellness FORT LAUDERDALE, June 07, 2025 (GLOBE NEWSWIRE) -- Super Feels Kava Kratom Shot, a plant-based wellness solution developed by Super Speciosa, has updated its official website to share new information about its daily supplement formulated to support mood balance and natural relaxation in adults. Now available across the U.S., the convenient liquid shot is designed for individuals seeking a natural, on-the-go wellness solution rooted in traditional botanicals. According to the official product website ( Super Feels is intended to work in harmony with the body's systems to support a sense of calm and well-being through its unique combination of kratom leaf extract and noble kava root. The company positions the product as a ready-to-use formula that easily integrates into modern lifestyles without the need for pills or powders. 'We wanted to create something portable, natural, and approachable—something people can use to help manage life's daily stressors in a more mindful way,' said a spokesperson for Super Speciosa. 'This product reflects our commitment to clean formulation and botanical tradition.' The company states that Super Feels Kava Kratom Shot is manufactured in GMP-compliant facilities that prioritize rigorous quality control and ingredient sourcing. It is crafted to meet the needs of adults seeking a plant-based option to support relaxation and mental clarity without artificial additives. As noted on the product website, Super Feels includes a satisfaction guarantee for first-time buyers. Those interested in exploring the formulation's functional use cases or ordering directly can access detailed information, customer FAQs, and secure checkout at the official site. About Super Feels by Super Speciosa Super Feels is part of Super Speciosa, a Florida-based wellness brand dedicated to premium kratom and herbal-based solutions. With a focus on transparency and natural sourcing, the company creates functional plant-based products that support modern wellness goals. Product and Contact Information Brand: Super Feels by Super SpeciosaWebsite: support@ +1 (888) 958-5401Mailing Address: 727 NE 3rd Ave, Suite 201, Fort Lauderdale, FL 33304, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: support@ Phone: +1 (888) 958-5401Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.
GMP TERBIUM-161 PRODUCT LAUNCHED BY TERTHERA BREDA, Netherlands, June 5, 2025 /PRNewswire/ -- TerThera B.V. has officially launched the world's first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide. Now, with the successful implementation of European Good Manufacturing Practices (GMP), TerThera's Terbium-161 meets the highest quality and safety standards required for clinical trials and patient care across Europe and beyond. This lowers regulatory barriers and accelerates the path to new therapies providing hospitals, clinicians, and researchers immediate access to this next-generation therapeutic radionuclide Terbium-161. A New Era in Cancer Treatment Terbium-161 NCA is a no-carrier-added, neutron-activated radionuclide uniquely suited for Radio Ligand Therapy (RLT). With an abundant emission of Auger electrons and high Linear Energy Transfer (LET), combined with similar chemical characteristics to well-known radiolanthanides, Tb-161 brings a high potential to decimate both primary tumors and (micro) metastases. When paired with proven targeting vectors like PSMA, SST, and FAPI analogues, Tb-161 demonstrates a bioequivalence while significantly increasing absorbed doses in all lesions, offering novel treatment options and strategies in cancer healthcare, improving the overall disease control and may even overcome radio-resistant disease. Global Vision, Local Innovation "This milestone is more than a regulatory achievement—it's a leap forward in our mission to bring Terbium-161 to patients worldwide," said Philippe van Overeem, CEO of TerThera. "GMP Terbium-161 is now a clinical reality, and this is just the beginning. We are actively constructing a large-scale production facility to meet the growing global demand and expand access to this promising radionuclide for optimized cancer treatments." With this launch, TerThera reaffirms its commitment to transforming the landscape of radiopharmaceuticals and leading the charge in precision oncology. About TerThera BV TerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT. support@ View original content: SOURCE TerThera Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Blue Mountain Launches Spring 2025 RAM Release, Advancing Asset Management for Life Sciences
Release enables smarter maintenance, seamless mobile workflows and the introduction of artificial intelligence for improved documentation search STATE COLLEGE, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Blue Mountain, the leader in GMP-compliant Enterprise Asset Management (EAM) software for life sciences, announces the launch of its Spring 2025 RAM Release, introducing advanced capabilities that drive operational excellence, maximize compliance, and empower mobile teams across the Life Sciences industry. The Spring 2025 release builds on RAM's trusted foundation by delivering enhancements in three transformative areas: Condition-Based Maintenance (CBM): Enables organizations to move beyond scheduled routines to smarter, condition-driven workflows. Real-time threshold management and automatic task generation ensure precision interventions, reducing downtime and cutting maintenance costs. RAM Mobile Enhancements: Teams can now execute work plans offline, submit mobile requests with photos, and maintain data integrity on the go. These updates dramatically reduce mean time to detection and improve documentation completeness. Artificial Intelligence: Now available in validation environments, RAMMY AI delivers instant, contextual answers sourced directly from validated documentation—slashing lookup times by up to 98% and unlocking daily productivity gains. 'Our Spring 2025 Release represents a major step toward predictive maintenance and mobile-first efficiency,' said Judy Fainor, Chief Technology Officer. 'With condition-based maintenance, powerful mobile capabilities, and the introduction of AI, we're enabling Life Sciences teams to work smarter, faster, and more compliantly than ever.' About Blue Mountain Blue Mountain is the leader in enterprise asset management for Life Sciences. For over 35 years, Blue Mountain has been committed to delivering innovative and high-quality solutions that ensure regulatory compliance, enable operational efficiency and equipment uptime, and provide insights that optimize asset lifecycle management. Trusted by more than 450+ Life Sciences companies, the Blue Mountain industry-leading cloud platform helps companies master end-to-end GMP asset management from set-up to installation and from training to validation. Blue Mountain is backed by Accel-KKR and headquartered in State College, PA. For more information, please visit and follow the company on LinkedIn. Media Contact: Christian Rockwellcarockwell@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
09-05-2025
- Business
- Business Standard
Remlife Global Partners With JiyaYu Lifesciences To Replace Animal Inputs In APIs Via Green Chemistry
PNN New Delhi [India], May 9: Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd. (India), is pleased to announce a forward-looking partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company. This collaboration is focused on replacing animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives. As part of the partnership, JiyaYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis. These technologies are designed to replace traditional animal-derived steps with sustainable, cost-effective, and regulatorycompliant bioprocesses. Remlife Global will scale up and commercialise these technologies at one or more GMP-compliant contract manufacturing sites across India, Singapore, Malta, Ireland, Belgium, and Italy. JiyaYu Lifesciences has in turn partnered with a UK-based R & D technology platform specialising in the development of fermentation and biocatalystbased alternatives to animal-origin pharmaceutical inputs. Through this collaboration, JiyaYu gains access to cutting-edge innovations that it will transfer to Remlife Global as fully scalable technologies. Each technology will be supported by detailed process dossiers and full technology transfer documents, enabling Remlife Global to implement, validate, and scale up the processes at approved GMP manufacturing sites. These solutions will support Remlife Global's vision of eliminating dependence on vulnerable and ethically complex supply chains, while capturing new commercial opportunities in global regulated markets. "Our collaboration with JiyaYu Lifesciences is a transformative move toward building a more ethical, resilient, and sustainable pharmaceutical supply chain." said Adarsh Munjal. Financial Outlook Each technology platform has a minimum commercial potential of Rs50 crore per product, with EBITDA margins estimated between 20% to 25%. Assuming a scale-up of two products per year, cumulative revenue and EBITDA could grow substantially: -FY26: 2 products | Rs100 Cr revenue | Rs20-25 Cr EBITDA -FY27: 4 products | Rs200 Cr revenue | Rs40-50 Cr EBITDA Moving Beyond Animal-Based Inputs Remlife Global's strategic direction is anchored in the belief that the future of pharmaceuticals lies in sustainable, animal-free production. Key reasons for this shift include: -Ethical and ESG Alignment: Modern pharmaceutical companies are under growing pressure to remove animal-based components from their supply chains. -Safety & Quality Control: Fermentation and biocatalyst-based systems offer superior consistency and eliminate the risk of contamination from animal-borne pathogens. -Supply Chain Resilience: Diseases, regulatory shifts, and geopolitical volatility all threaten the availability of animal-derived inputs. -Environmental Benefits: Traditional animal-derived raw materials are linked to high emissions, land use, and water consumption. -Industry Momentum: Leading global pharma firms are rapidly adopting bio-based and cruelty-free technologies in their development pipelines. About Remlife Global PTE LTD. Remlife Global PTE LTD. is the international innovation arm of Remedium Lifecare Ltd. (India), a BSE-listed pharmaceutical company. With a focus on R & D commercialisation and strategic collaborations, Remlife Global is driving the transition to sustainable API Contract manufacturing across multiple global jurisdictions. Media Contact Adarsh Munjal Remlife Global PTE LTD. Email: info@ (ADVERTORIAL DISCLAIMER: The above press release has been provided by PNN. ANI will not be responsible in any way for the content of the same)
